Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
Verywell Health on MSN
6 types of treatment for complement 3 glomerulopathy
Medically reviewed by Matthew Wosnitzer, MD Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback